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Abstract
Background The present study aimed to provide updated
data on anaemia prevalence and management in cancer
patients undergoing systemic therapy in Spain.
Methods This was a multicenter, observational, cross-
sectional study performed in 2008. Eligible patients were
C18 years, with non-myeloid malignancies treated with
systemic therapy [chemotherapy (CT), hormonal therapy
or immunotherapy]. Anaemia was defined according to
WHO as haemoglobin (Hb) \ 12 g/dL.
Results The study included 214 patients with a median
age of 63 years (range 20–91), 58 % women, 73 % with
solid tumours, and 79 % with advanced disease. CT was
used in 91 % of patients (26 % with platinum compounds),
hormonal therapy in 8.5 %, and immunotherapy in 8.5 %.
In our study, 48.1 % of patients [95 % confidence interval
(CI) 45.2–58.6] showed anaemia (31 % symptomatic):
42.0 % mild (10 B Hb B 11.9 g/dL), 5.6 % moderate
(8 B Hb B 9.9 g/dL), and 0.5 % severe (Hb \ 8 g/dL).
A higher prevalence was observed in patients treated with
CT (51 vs. 20 %, p = 0.01), platinum-based CT (70 vs.
47 %, p = 0.01) or palliative CT (61 vs. 39 %, p = 0.003).
Anaemia was also more frequent in patients with more than
three lines of CT (83 %) and in the fourth or subsequent
CT cycle (58 %). Management in the previous 4 weeks in
patients with anaemia was: 62 % did not receive treatment
(92 % mild), 24 % received erythropoiesis-stimulating
agents (ESAs), 14 % received iron and 8.7 % received
transfusion.
Conclusions In Spanish hospitals, about half of patients
with non-myeloid malignancies undergoing systemic ther-
apy fulfilled anaemia criteria (87 % mild). Approximately
two-third of patients with anaemia do not receive specific
treatment and ESA use is below current guidelines.
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Introduction
Most cancer patients suffer anaemia during the course of
the disease or the treatment, in particular those patients
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receiving myelosuppressive chemotherapy [1]. Severe
anaemia (\8 g/dL) can lead to the onset of cardiovascular
and respiratory symptoms, such as tachycardia, hypoten-
sion and dyspnoea, although less severe anaemia can also
produce a range of symptoms such as fatigue, exercise
intolerance, decreased appetite and reduced general wel-
fare [2]. In addition, anaemia has been shown to influence
the evolution of disease, increasing the risk of progression
and decreasing overall survival [3, 4].
Significant progress has been made in the prevention
and management of chemotherapy-induced anaemia.
Current therapeutic options include iron supplementation,
administration of erythropoiesis-stimulating agents (ESAs)
and blood transfusion. Several guidelines have been pub-
lished with specific recommendations [5–7], like the 2007
European Organization for Research and Treatment of
Cancer (EORTC) guidelines [6]. The European Cancer
Anaemia Survey (ECAS) [8], the first major epidemio-
logical study on anaemia conducted in 2001, revealed a
high prevalence and incidence, and highlighted that many
patients (some of them with haemoglobin [Hb] \ 10 g/dL
and/or symptomatic anaemia) received no specific treat-
ment. Since then, some studies in particular countries
like France [9], Germany [10] and Belgium [11], have
provided updated and country-specific information on
anaemia management and fulfilment of guidelines. In the
Spanish context, there is no recent data available in this
field. This study aims to provide accurate and relevant
information on the prevalence and patterns of treatment of
anaemia in Spanish cancer patients treated with systemic
therapy with or without radiation therapy in the clinical
practice.
Patients and methods
This was an observational, multicenter, cross-sectional
study in 21 Spanish hospitals. We consecutively included
all patients who attended the clinic during a particular
day of the week from May 19 to May 23, 2008 (to be
chosen by each site according to their availability), and
fulfilled selection criteria: age C18 years; patients diag-
nosed with non-myeloid tumour (except for myelodys-
plastic syndromes), undergoing treatment with systemic
therapy (CT, hormone therapy or immunotherapy), with
or without radiation therapy; patients who had received
the last cycle of treatment within the previous 4 weeks;
patients who had a blood test (including Hb value)
performed on the date of the visit or within the past
72 h; non-hospitalized patients. The protocol was
approved by an independent ethics committee, and all
patients gave their written informed consent before
enrolment.
Data on clinical characteristics, type of cancer, treat-
ment for anaemia and Hb levels were collected for the
baseline visit and for the past 4 weeks. We defined the
degree of anaemia according to World Health Organization
(WHO) as follows: mild anaemia, Hb between 11.9 and
10 g/dL; moderate anaemia, Hb between 9.9 and 8 g/dL;
severe anaemia, Hb \ 8 g/dL.
Statistical analysis was descriptive. The prevalence of
anaemia in the entire study population and in specific
subgroups (by type and stage of tumour, age category, sex,
presence or absence of symptoms and type and character-
istics of systemic therapy) was described. Treatments for
anaemia received in the 4 weeks prior to inclusion and
provided on that day were also described (no treatment,
transfusion, iron supplements or vitamins, ESAs). We
performed an exploratory analysis to analyze the relation-
ship between patient characteristics or treatment and the
presence of anaemia. For qualitative variables, the rela-
tionship was assessed using Chi Square tests (or Fisher’s
exact test if it was applicable), and for quantitative vari-
ables, using Student’s t tests. Statistical analyses were
performed with the SAS package-version 9.0 (SAS
Institute, Cary, NC, USA).
Results
Study population
The study included 214 patients with a median age of
63 years (range 20–91), 58 % women and 73 % with solid
tumours. The most common tumour types were breast
(37.6 %), gastrointestinal (23.6 %) and lung cancer
(19.7 %). Most patients (91 %) were receiving CT (of
which 26 % received platinum compounds), 8.5 % hor-
mone therapy, and 8.6 % immunotherapy (Table 1).
The main reason for the visit was CT administration
(74.8 %), followed by routine follow-up visit (25.7 %),
radiotherapy administration (4.7 %) and other reasons
(5.2 %). The median time since diagnosis was 8.4 months
(range 1.2–240).
Prevalence of anaemia
Overall, 48.1 % of patients (95 % CI 45.2–58.6) had
anaemia (of whom 13 % had levels \10 g/dL and 31 %
were symptomatic) (Fig. 1).
Median Hb level in the overall sample was 12.0 g/dL
(range 7.4–16.1) (Table 2). The proportion of patients who
reported symptoms of anaemia in the current visit was the
same as in the previous 4 weeks. Only three patients with
symptoms at the current visit did not have anaemia
according to the laboratory test.
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Factors related to anaemia
There was a trend towards a higher prevalence of anaemia in
women (52 vs. 42 % in men, p = 0.140) and in patients with
solid tumours (52 vs. 37 % in patients with haematological
malignancies, p = 0.094) (Fig. 2). No association between
anaemia and age, stage or tumour type was observed (data
not shown). A higher prevalence was found in patients with
symptoms of anaemia in the last 4 weeks (82 vs. 40 % in
patients without symptoms, p \ 0.0001), and in patients
treated with CT (51 vs. 21 % in patients treated with hor-
monal therapy or immunotherapy, p = 0.013), platinum-
based CT (70 vs. 47 % in patients with non-platinum based
CT, p = 0.013) or palliative CT (61 vs. 39 % in patients with
curative CT, p = 0.003) (Fig. 2).
There were no differences in the prevalence of anaemia
between patients with CT receiving monotherapy or com-
bination therapy (52 vs. 49 %, p = 0.457). The adminis-
tration of concomitant radiotherapy was not related to
anaemia either (52 vs. 48 %, p = 0.944).
The proportion of patients with anaemia was significantly
higher in patients with more than three lines of CT (83 vs. 46,
54 and 44 % in patients undergoing first-, second- and third-
line of CT, respectively, p = 0.006) and in patients in the






Age (years), median (range) 63 (20; 91) Chemotherapy, n (%) 193 (91.0)
Women, n (%) 124 (57.9) Adjuvantc 37 (20.7)
Reason for visit, n (%) Advanced stagec 142 (79.3)
Chemotherapy 160 (74.8) Line of advanced stage, n (%)d
Monitoring visit 55 (25.7) First 76 (53.9)
Radiotherapy 10 (4.7) Second 37 (26.2)
Therapy (antiemetics…) 5 (2.3) Third 16 (11.3)
Treatment of complications 1 (0.5) More than third 12 (8.5)
RBC transfusion 1 (0.5) Intention, n (%)e
Other reasons 3 (1.4) Curative 87 (46.8)
Time since diagnosis (years), median (range) 0.7 (0.1–20) Palliative 99 (53.2)
Primary tumour, n (%) Cycle number, median (range) 4 (1; 19)
Solid tumour 157 (73.4) Type of therapy, n (%)f
Breast 59 (37.6) Monotherapy 69 (36.7)
Gastrointestinal 37 (23.6) Polychemotherapy 119 (63.3)
Lung 31 (19.7) Use of platinums, n (%)g
Other 30 (19.1) With platinum 40 (25.8)
Haematological tumour 57 (26.6) Without platinum 115 (74.2)
Lymphoma 14 (24.6) Radiotherapy, n (%)h 21 (10.0)
Myeloma 31 (54.4) Hormonal therapy, n (%)i 18 (8.5)
Other 12 (21.0) Immunotherapy, n (%)j 18 (8.6)
Metastasis (only solid tumours), n (%)a 98 (63.2) Targeted therapy, n (%)j 20 (9.5)
Stage III–IV (only haematological tumours), n (%)b 27 (65.8) Other systemic treatments, n (%)j 17 (8.1)
ECOG Eastern Cooperative Oncology Group, RBC red blood cells, SD standard deviation
a Valid n = 155, b valid n = 41, c valid n = 179, d valid n = 141, e valid n = 186, f valid n = 188, g valid n = 155, h valid n = 211, i valid
n = 213, j valid n = 210
Fig. 1 Prevalence of anaemia in cancer patients treated with systemic
therapy
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fourth or subsequent CT cycles, compared with patients in
the first three cycles (58 vs. 41 %, p = 0.028).
No significant differences were found in mean leukocyte
or platelet count between patients with and without anae-
mia (data not shown).
Anaemia management
In patients with anaemia (n = 103), the management in the
previous 4 weeks was as follows: 62.1 % received no spe-
cific treatment (of whom 91.9 % had mild anaemia), 24.0 %
received ESA, 13.6 % received iron supplementation and
8.7 % received transfusion (Fig. 3). The use of transfusion
in the previous 4 weeks was higher in patients with mod-
erate or severe anaemia, compared to patients with mild
anaemia (23.1 vs. 5.6 %, p \ 0.0001). Thereby, 37.5 % of
patients who received transfusion during the previous
4 weeks (3 out of 8) still had moderate or severe anaemia.
In the current visit, the percentage of patients without
any treatment for anaemia increased to 74.8 % (of whom
94.9 % had mild anaemia). Sixty-nine percent of the
patients with moderate or severe anaemia received treat-
ment, compared with only 18 % of patients with mild
anaemia (p \ 0.0001). Only two patients were prescribed a
transfusion at the study visit (one received only transfusion
and the other one received transfusion, iron and ESA), both
having moderate or severe anaemia.
Among the 25 patients who received any anaemia treat-
ment at the study visit, 18 patients received ESA’s (17.5 % of
anaemic subjects). Darbepoetin alfa was the most commonly
used agent (13 patients, four patients received epoetin beta,
and 1 patient received epoetin alfa). The use of ESA’s was
more frequent in patients with moderate or severe anaemia
(46 vs. 13 % in patients with mild anaemia, p = 0.012).
Among patients prescribed ESA’s, the mean Hb in patients
with mild or moderate-severe anaemia was 10.5 and
Fig. 2 Prevalence of anaemia
in different subgroups according
to patient characteristics, type of
tumour, symptoms related to
anaemia and systemic therapy
Table 2 Haematological parameters and symptoms of anaemia
Variable
Haemoglobin (g/dL) Valid n 214




Leukocytes (9109/L) Valid n 214




Platelets (9109/L) Valid n 214




During the last 4 weeks,
has the patient had symptoms
related to anaemia?
Valid n 206 (100.0 %)
Yes 34 (16.5 %)
No 172 (83.5 %)
In the current visit, has
the patient symptoms
related to anaemia?
Valid n 208 (100.0 %)
Yes 35 (16.8 %)
No 173 (83.2 %)
SD standard deviation
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8.2 g/dL, respectively. Iron supplementation was used in
13 patients (12.6 % of anaemic subjects).
Discussion
We present information on the prevalence and management
of anaemia in an unselected cohort of cancer patients
undergoing systemic therapy in the Spanish setting. We
found a prevalence of anaemia (defined as Hb \ 12 g/dL)
of approximately 50 %, which is similar to that found
in other contemporary studies from European countries
[9–11].
In the ECAS, conducted in 2001, the prevalence of
anaemia at enrolment was lower (39 %), but the proportion
of anaemic subjects not receiving treatment was compa-
rable to ours (more than 60 %) [8]. Recent data from
France suggest a better management of anaemia in this
country, with ESA administration in approximately two-
third of anaemic patients, and only 17 % non-treated [9]. In
the Belgian study with the same design as the present one,
the prevalence of anaemia was comparable (56 %), but a
higher relative proportion of moderate versus mild anaemia
was found (threefold to that of the Spanish cohort) [11].
They also observed more anaemia in patients with
haematological malignancies (73 %) compared to solid
tumours, which disagrees with our results. The fact that
they did not exclude patients with myelodysplastic syn-
dromes (at high risk of anaemia) can partially explain this
finding, but probably there are other differences involved
[for example, more use of platinum-based regimens (37 vs.
26 % in our cohort), or more proportion of advanced dis-
ease]. Regarding anaemia management, there were also
important disparities with our results: a higher proportion
of treated patients (almost 50 %) and more transfusions.
Iron use was similar [11].
We observed a strong association between CT admin-
istration and anaemia, as previously reported in the ECAS
[12]. Among CT-related factors, more than three lines of
treatment or more than three cycles were associated to a
higher risk of anaemia. Similarly, during ECAS, the
prevalence of anaemia increased progressively from cycle
1 to cycle 6 [13]. The observed association with palliative
CT probably reflects the degree of severity of the disease
and its impact on erythropoiesis. Interestingly, the preva-
lence of anaemia was not different in patients receiving
mono-CT as opposed to poly-CT, but it was higher in
patients receiving platinum-based regimens (70 vs. 47 %).
We did not find any significant influence of radiotherapy
administration. A model developed by Barret et al. [14] to
predict anaemia development in cancer patients initiating
CT included the following variables as the most important
factors: low initial Hb (B12.9 g/dL in females, and
B13.4 g/dL in males); cancer type other than gastro-
intestinal/colorectal cancer; treatment with platinum CT,
and female gender. We did not analyze the prevalence by
tumour subtype, due to sample size limitation, but we
confirm a strong association with platinum-based CT.
Since ECAS, several guidelines have provided recom-
mendations for ESA use in cancer patients. The EORTC
[6] guidelines recommend to treat all patients with Hb
levels below 9 g/dL (who were only a small percentage of
our sample), and all symptomatic patients with levels
between 9 and 11 g/dL. The Anaemia Cancer Treatment
(A.C.T.) study was a retrospective, extensive review of
anaemic patients with cancer treated with ESAs investi-
gating patterns of use according to EORTC guidelines [15].
It concluded that, in 2007, most European patients were
treated per guidelines, except for low iron supplementation
rates [16]. A prospective German study in cancer patients
with anaemia observed that physicians preferred ESA as
first-line treatment in patients with solid tumours, but in
patients with lymphoproliferative malignancies, transfu-
sions or correction of underlying disorders was preferred.
They also reported underuse of intravenous iron therapy
[10]. In our cohort, around one-third of anaemic subjects
Fig. 3 Therapeutic management of anaemia (previous 4 weeks and current visit) in patients with Hb \ 12 g/dL at study inclusion (n = 103)
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were symptomatic, which means that at least the same
amount of individuals would benefit from receiving ESAs.
Since only 17 % of patients were being treated with
erythropoietic agents, we can conclude that the EORTC
guidelines were still not fully implemented during 2008 in
the clinical practice of Spanish Oncology or Oncohema-
tology services. Current guidelines of the Spanish Society
of Medical Oncology (SEOM) about the use of ESAs in
cancer patients [17] were published in 2009, after the study
completion. They established that, since ESA treatment
increases the Hb level and decreases the red blood cell
transfusion requirements, ESAs should be used within the
approved indications in patients undergoing chemotherapy
treatment, beginning at an Hb level below 11 g/dL and
maintaining it around 12 g/dL, with iron supplements if
necessary. Thus, our data also shows that management of
anaemia in Spain needs to be updated according to local
guidelines.
Despite the concerns about use of ESAs, all meta-
analyses considering only clinical trials performed under
the approved indication (patients receiving chemotherapy)
support their safety and clinical benefit in the treatment
of chemotherapy-induced anaemia [18–23], including a
reduction in transfusion needs both in solid tumours and in
haematological malignancies [24, 25]. In the larger meta-
analysis conducted until now, the use of ESAs was neutral
with regard to survival and disease progression [26]. In this
meta-analysis, it was also demonstrated that the use of
ESAs is associated with an increased risk of venous
thromboembolism (odds ratio = 1.4) [26]. Regarding the
increase in the risk for thromboembolic events [23, 27], it
must be taken into account specially in patients with car-
diovascular disease, in whom the ESA dose must be
adjusted according to patient characteristics to avoid an
excessive change in plasma volume and maintaining a
consistent Hb level [28].
The main limitations of our study are the limited sample
size, that does not allow to explore differences in the
prevalence and management of anaemia between tumour
subtypes, for example, and the cross-sectional design,
which does not allow for causal inferences.
Conclusion
In Spanish hospitals, about half of patients with non-
myeloid malignancies undergoing systemic therapy suffer
from anaemia. Chemotherapy administration, especially
if it contains platinum compounds or represents an
advanced-line therapy, is associated with a high risk of
anaemia. Our results show that approximately two-third
of patients with anaemia do not receive specific treat-
ment and that ESAs are underused according to current
EORTC and local SEOM guidelines. Since the treatment
of anaemia with ESAs (and adequate iron supplementa-
tion) can significantly improve patients’ quality of life
and may also improve the clinical outcome, it is advis-
able to review and optimize anaemia management in the
clinical practice of Spanish Oncology and Hematology
services.
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